• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Fortress Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/14/25 4:10:37 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBIO alert in real time by email
    Fortress Biotech, Inc._August 14, 2025
    0001429260false0001429260us-gaap:CommonStockMember2025-08-142025-08-140001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2025-08-142025-08-1400014292602025-08-142025-08-14

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

    Date of report (Date of earliest event reported): August 14, 2025

    Fortress Biotech, Inc.

    (Exact Name of Registrant as Specified in Charter)

    ​

    Delaware
     (State or Other Jurisdiction
    of Incorporation)

       

    001-35366
     (Commission File Number)

        

    20-5157386
    (IRS Employer
    Identification No.)

    ​

    1111 Kane Concourse, Suite 301

    Bay Harbor Islands, FL 33154

    (Address of Principal Executive Offices)

    (781) 652-4500

    (Registrant’s telephone number, including area code)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act.

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

    ☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    Title of each class

    Trading Symbol(s)

    Name of each exchange on which registered

    Common Stock

    FBIO

    Nasdaq Capital Market

    9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

    FBIOP

    Nasdaq Capital Market

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Item 2.02.    Results of Operations and Financial Condition.

    ​

    On August 14, 2025, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the quarter ended June 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report.

     

    The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.

    ​

    Item 9.01.    Financial Statements and Exhibits.

    ​

    (d)    Exhibits.

    The following exhibit is furnished herewith:

    99

    Exhibit
    Number

        

    Description

    99.1

     

    Press Release, dated August 14, 2025

    104

     

    Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    Fortress Biotech, Inc.

    ​

    (Registrant)

    ​

    ​

    Date: August 14, 2025

    ​

    ​

    ​

     

    By:

    /s/ Lindsay A. Rosenwald, M.D.

     

     

    Lindsay A. Rosenwald, M.D.

     

     

    Chairman, President and Chief Executive Officer

    ​

    ​

    ​

    ​

    ​

    Get the next $FBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FBIO

    DatePrice TargetRatingAnalyst
    3/15/2024$10.00Buy
    ROTH MKM
    8/4/2022$6.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $FBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Jin David was granted 5,000 shares, increasing direct ownership by 0.40% to 1,245,893 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    4/1/25 4:20:16 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lobell J Jay was granted 49,383 shares, increasing direct ownership by 43% to 165,075 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/3/25 4:28:30 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Klein Dov was granted 49,383 shares, increasing direct ownership by 92% to 102,783 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    1/3/25 4:20:17 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

    Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed a $205 million Series A financing to support the advancement of global Phase 3 clinical studies evaluating dotinurad for the treatment of gout. The financing rou

    10/1/25 8:05:56 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") relating to the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group") assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium. Cyprium expects its partner, Sen

    10/1/25 8:00:46 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Participate in September 2025 Investor Conferences

    SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences. Details of the events are as follows: H.C. Wainwright 27th Annual Global Investment Conference Date and Time: Monday, September 8, 2025, at 1:30 p.m. ETLocation: New York CityFormat: Fireside

    9/3/25 8:30:57 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    SEC Filings

    View All

    Fortress Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    10/1/25 8:45:20 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Fortress Biotech Inc.

    10-Q - Fortress Biotech, Inc. (0001429260) (Filer)

    8/14/25 4:16:41 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Fortress Biotech, Inc. (0001429260) (Filer)

    8/14/25 4:10:37 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT, CEO & CHAIRMAN Rosenwald Lindsay A Md bought $1,404,581 worth of shares (763,359 units at $1.84), increasing direct ownership by 26% to 3,657,264 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    9/25/24 4:45:04 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO & Chairman Rosenwald Lindsay A Md bought $37,418 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (5,000 units at $7.48), increasing direct ownership by 4% to 127,500 units (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/15/24 4:05:14 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Jin David bought $3,750 worth of SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK (500 units at $7.50) (SEC Form 4)

    4 - Fortress Biotech, Inc. (0001429260) (Issuer)

    7/12/24 8:42:21 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM resumed coverage on Fortress Biotech with a new price target

    ROTH MKM resumed coverage of Fortress Biotech with a rating of Buy and set a new price target of $10.00

    3/15/24 7:18:10 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ladenburg Thalmann initiated coverage on Fortress Biotech with a new price target

    Ladenburg Thalmann initiated coverage of Fortress Biotech with a rating of Buy and set a new price target of $6.00

    8/4/22 7:17:35 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Fortress Biotech with a new price target

    Roth Capital reiterated coverage of Fortress Biotech with a rating of Buy and set a new price target of $5.00 from $4.50 previously

    4/20/21 8:28:52 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortress Biotech Inc.

    SC 13G - Fortress Biotech, Inc. (0001429260) (Subject)

    10/25/24 10:15:19 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fortress Biotech Inc.

    SC 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)

    9/25/24 4:45:18 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Fortress Biotech Inc. (Amendment)

    SC 13G/A - Fortress Biotech, Inc. (0001429260) (Subject)

    2/14/24 4:51:41 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FBIO
    Financials

    Live finance-specific insights

    View All

    Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing

    Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics, Inc. ("Crystalys"), in which Urica maintains an equity position, closed a $205 million Series A financing to support the advancement of global Phase 3 clinical studies evaluating dotinurad for the treatment of gout. The financing rou

    10/1/25 8:05:56 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") relating to the New Drug Application ("NDA") for CUTX-101 (copper histidinate), intended to treat Menkes disease in pediatric patients. In December 2023, Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group") assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium. Cyprium expects its partner, Sen

    10/1/25 8:00:46 AM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of UNLOXCYT™ (cosibelimab-ipdl) FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults MIAMI, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and advancing a

    8/14/25 4:05:03 PM ET
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care